D2B: Direct-to-Biology Platform

Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and time-saving approach that integrates the expertise of medicinal chemistry, high-throughput synthesis and assays, and computer-aided drug design, streamlining iterative design-synthesis-test cycles by directly testing high-throughput synthesized compounds in biological assays.

Starting from a primary hit or ligand, our D2B platform enables rapid go/no-go decisions and hit triage, resulting in more efficient research outcomes with a typical timeline of just 2 – 3 weeks per cycle.